Literature DB >> 23343157

Nanomedicine for uterine leiomyoma therapy.

Hazem Ali1, Gokhan Kilic, Kathleen Vincent, Massoud Motamedi, Erik Rytting.   

Abstract

BACKGROUND: The purpose of this work was to engineer polymeric nanoparticles to encapsulate and deliver 2-methoxyestradiol, a potential antitumor drug for treatment of uterine leiomyoma (fibroids), the most common hormone-dependent pathology affecting women of reproductive age. METHODS/
RESULTS: Encapsulation efficiency and drug release from the nanoparticles were monitored by HPLC. Cell morphology and in vitro cytotoxicity experiments were carried out in a human leiomyoma cell line. The nanoparticles displayed high encapsulation efficiency (>86%), which was verified by differential scanning calorimetry and x-ray diffraction. Excellent long-term stability of the nanoparticles and gradual drug release without burst were also observed. Cellular uptake of fluorescent nanoparticles was confirmed by confocal imaging. The drug-loaded poly(lactic acid) and poly(lactic-co-glycolic acid) nanoparticles induced cytotoxicity in human leiomyoma cells to a significantly greater extent than the free drug at 0.35 µM.
CONCLUSION: This novel approach represents a potential fertility-preserving alternative to hysterectomy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23343157      PMCID: PMC3754434          DOI: 10.4155/tde.12.144

Source DB:  PubMed          Journal:  Ther Deliv        ISSN: 2041-5990


  41 in total

1.  The frequency of uterine leiomyomas.

Authors:  S F Cramer; A Patel
Journal:  Am J Clin Pathol       Date:  1990-10       Impact factor: 2.493

Review 2.  Epidemiology of myomas.

Authors:  Mark Payson; Phyllis Leppert; James Segars
Journal:  Obstet Gynecol Clin North Am       Date:  2006-03       Impact factor: 2.844

Review 3.  Drug targeting with nanoparticles.

Authors:  J Kreuter
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Jul-Sep       Impact factor: 2.441

4.  Electron microscopy of frozen biological suspensions.

Authors:  J Lepault; F P Booy; J Dubochet
Journal:  J Microsc       Date:  1983-01       Impact factor: 1.758

Review 5.  Uterine leiomyomata: etiology, symptomatology, and management.

Authors:  V C Buttram; R C Reiter
Journal:  Fertil Steril       Date:  1981-10       Impact factor: 7.329

6.  Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors.

Authors:  William L Dahut; Nehal J Lakhani; James L Gulley; Philip M Arlen; Elise C Kohn; Herbert Kotz; Debbie McNally; Allyson Parr; Diana Nguyen; Sherry X Yang; Seth M Steinberg; Jürgen Venitz; Alex Sparreboom; William D Figg
Journal:  Cancer Biol Ther       Date:  2006-01-22       Impact factor: 4.742

7.  Catechol-O-methyltransferase polymorphism is associated with increased uterine leiomyoma risk in different ethnic groups.

Authors:  Ayman Al-Hendy; Salama A Salama
Journal:  J Soc Gynecol Investig       Date:  2006-02

8.  2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma.

Authors:  Justin L Ricker; Zhong Chen; Xin Ping Yang; Victor S Pribluda; Glenn M Swartz; Carter Van Waes
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

9.  Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method.

Authors:  M F Zambaux; F Bonneaux; R Gref; P Maincent; E Dellacherie; M J Alonso; P Labrude; C Vigneron
Journal:  J Control Release       Date:  1998-01-02       Impact factor: 9.776

10.  Relative overexpression of collagen type I and collagen type III messenger ribonucleic acids by uterine leiomyomas during the proliferative phase of the menstrual cycle.

Authors:  E A Stewart; A J Friedman; K Peck; R A Nowak
Journal:  J Clin Endocrinol Metab       Date:  1994-09       Impact factor: 5.958

View more
  7 in total

Review 1.  Drug delivery for the treatment of endometriosis and uterine fibroids.

Authors:  David R Friend
Journal:  Drug Deliv Transl Res       Date:  2017-12       Impact factor: 4.617

2.  Microvascular and mitochondrial dysfunction in the female F1 generation after gestational TiO2 nanoparticle exposure.

Authors:  Phoebe A Stapleton; Cody E Nichols; Jinghai Yi; Carroll R McBride; Valerie C Minarchick; Danielle L Shepherd; John M Hollander; Timothy R Nurkiewicz
Journal:  Nanotoxicology       Date:  2015-09-04       Impact factor: 5.913

3.  Transport of digoxin-loaded polymeric nanoparticles across BeWo cells, an in vitro model of human placental trophoblast.

Authors:  Norah A Albekairi; Sanaalarab Al-Enazy; Shariq Ali; Erik Rytting
Journal:  Ther Deliv       Date:  2015

4.  Statin use and uterine fibroid risk in hyperlipidemia patients: a nested case-control study.

Authors:  Mostafa A Borahay; Xiao Fang; Jacques G Baillargeon; Gokhan S Kilic; Darren F Boehning; Yong-Fang Kuo
Journal:  Am J Obstet Gynecol       Date:  2016-06-28       Impact factor: 8.661

5.  Liposomal 2-Methoxyestradiol Nanoparticles for Treatment of Uterine Leiomyoma in a Patient-Derived Xenograft Mouse Model.

Authors:  Mostafa A Borahay; Kathleen L Vincent; Massoud Motamedi; Ibrahim Tekedereli; Salama A Salama; Bulent Ozpolat; Gokhan S Kilic
Journal:  Reprod Sci       Date:  2020-07-06       Impact factor: 3.060

Review 6.  Nanoparticles in pregnancy: the next frontier in reproductive therapeutics.

Authors:  Natasha Pritchard; Tu'uhevaha Kaitu'u-Lino; Lynda Harris; Stephen Tong; Natalie Hannan
Journal:  Hum Reprod Update       Date:  2021-02-19       Impact factor: 17.179

Review 7.  Nanomedicine applications in women's health: state of the art.

Authors:  Oliver Lloyd-Parry; Charlotte Downing; Eisa Aleisaei; Celine Jones; Kevin Coward
Journal:  Int J Nanomedicine       Date:  2018-03-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.